APO Research
Talk to an analyst

APO RESEARCH · REPORT

Attention Deficit Hyperactivity Disorder Therapeutics

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Attention Deficit Hyperactivity Disorder Therapeutics Industry Growth and Trends Forecast to 2032

2 January 2026101 pages

Choose your research edition.

Industry ResearchAttention Deficit Hyperactivity Disorder Therapeutics Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Attention Deficit Hyperactivity Disorder Therapeutics Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Attention Deficit Hyperactivity Disorder Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Attention Deficit Hyperactivity Disorder Therapeutics Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

According to APO Research, the global Attention Deficit Hyperactivity Disorder Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Attention Deficit Hyperactivity Disorder Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Attention Deficit Hyperactivity Disorder Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Attention Deficit Hyperactivity Disorder Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Attention Deficit Hyperactivity Disorder Therapeutics market include Takeda, Johnson & Johnson, Novartis, Eli Lilly, Tris Pharma, Purdue Parma, Noven Pharmaceuticals, Neos Therapeutics and Mallinckrodt, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Attention Deficit Hyperactivity Disorder Therapeutics market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Attention Deficit Hyperactivity Disorder Therapeutics market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Attention Deficit Hyperactivity Disorder Therapeutics market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Attention Deficit Hyperactivity Disorder Therapeutics.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Attention Deficit Hyperactivity Disorder Therapeutics market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Attention Deficit Hyperactivity Disorder Therapeutics Market by Company

Takeda

Johnson & Johnson

Novartis

Eli Lilly

Tris Pharma

Purdue Parma

Noven Pharmaceuticals

Neos Therapeutics

Mallinckrodt

Amneal Pharmaceuticals

Attention Deficit Hyperactivity Disorder Therapeutics Segment by Type

Stimulant

Non-stimulant

Attention Deficit Hyperactivity Disorder Therapeutics Segment by Application

Hospital Pharmacy

Retail Pharmacy

Attention Deficit Hyperactivity Disorder Therapeutics Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Attention Deficit Hyperactivity Disorder Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Attention Deficit Hyperactivity Disorder Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Attention Deficit Hyperactivity Disorder Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Attention Deficit Hyperactivity Disorder Therapeutics companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Share by Region (2021-2026) Table 4. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Share by Region (2027-2032) Table 6. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size Share by Type (2021-2026) Table 9. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size Share Forecasted by Type (2027-2032) Table 11. North America Attention Deficit Hyperactivity Disorder Therapeutics Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Attention Deficit Hyperactivity Disorder Therapeutics Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Attention Deficit Hyperactivity Disorder Therapeutics Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Attention Deficit Hyperactivity Disorder Therapeutics Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Attention Deficit Hyperactivity Disorder Therapeutics Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Attention Deficit Hyperactivity Disorder Therapeutics Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Attention Deficit Hyperactivity Disorder Therapeutics Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Attention Deficit Hyperactivity Disorder Therapeutics Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Attention Deficit Hyperactivity Disorder Therapeutics Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Attention Deficit Hyperactivity Disorder Therapeutics Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size Share by Application (2021-2026) Table 24. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size Share Forecasted by Application (2027-2032) Table 26. North America Attention Deficit Hyperactivity Disorder Therapeutics Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Attention Deficit Hyperactivity Disorder Therapeutics Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Attention Deficit Hyperactivity Disorder Therapeutics Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Attention Deficit Hyperactivity Disorder Therapeutics Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Attention Deficit Hyperactivity Disorder Therapeutics Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Attention Deficit Hyperactivity Disorder Therapeutics Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Attention Deficit Hyperactivity Disorder Therapeutics Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Attention Deficit Hyperactivity Disorder Therapeutics Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Attention Deficit Hyperactivity Disorder Therapeutics Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Attention Deficit Hyperactivity Disorder Therapeutics Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Attention Deficit Hyperactivity Disorder Therapeutics Industry Trends Table 37. Attention Deficit Hyperactivity Disorder Therapeutics Industry Drivers Table 38. Attention Deficit Hyperactivity Disorder Therapeutics Industry Opportunities and Challenges Table 39. Attention Deficit Hyperactivity Disorder Therapeutics Industry Restraints Table 40. Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue Market Share by Company (2021-2026) Table 42. Global Attention Deficit Hyperactivity Disorder Therapeutics Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Attention Deficit Hyperactivity Disorder Therapeutics Key Company Headquarters & Area Served Table 44. Global Attention Deficit Hyperactivity Disorder Therapeutics Company, Product Type & Application Table 45. Global Attention Deficit Hyperactivity Disorder Therapeutics Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Attention Deficit Hyperactivity Disorder Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Takeda Company Information Table 49. Takeda Business Overview Table 50. Takeda Attention Deficit Hyperactivity Disorder Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Takeda Attention Deficit Hyperactivity Disorder Therapeutics Product Portfolio Table 52. Takeda Recent Development Table 53. Johnson & Johnson Company Information Table 54. Johnson & Johnson Business Overview Table 55. Johnson & Johnson Attention Deficit Hyperactivity Disorder Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Johnson & Johnson Attention Deficit Hyperactivity Disorder Therapeutics Product Portfolio Table 57. Johnson & Johnson Recent Development Table 58. Novartis Company Information Table 59. Novartis Business Overview Table 60. Novartis Attention Deficit Hyperactivity Disorder Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Novartis Attention Deficit Hyperactivity Disorder Therapeutics Product Portfolio Table 62. Novartis Recent Development Table 63. Eli Lilly Company Information Table 64. Eli Lilly Business Overview Table 65. Eli Lilly Attention Deficit Hyperactivity Disorder Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Eli Lilly Attention Deficit Hyperactivity Disorder Therapeutics Product Portfolio Table 67. Eli Lilly Recent Development Table 68. Tris Pharma Company Information Table 69. Tris Pharma Business Overview Table 70. Tris Pharma Attention Deficit Hyperactivity Disorder Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Tris Pharma Attention Deficit Hyperactivity Disorder Therapeutics Product Portfolio Table 72. Tris Pharma Recent Development Table 73. Purdue Parma Company Information Table 74. Purdue Parma Business Overview Table 75. Purdue Parma Attention Deficit Hyperactivity Disorder Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Purdue Parma Attention Deficit Hyperactivity Disorder Therapeutics Product Portfolio Table 77. Purdue Parma Recent Development Table 78. Noven Pharmaceuticals Company Information Table 79. Noven Pharmaceuticals Business Overview Table 80. Noven Pharmaceuticals Attention Deficit Hyperactivity Disorder Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Noven Pharmaceuticals Attention Deficit Hyperactivity Disorder Therapeutics Product Portfolio Table 82. Noven Pharmaceuticals Recent Development Table 83. Neos Therapeutics Company Information Table 84. Neos Therapeutics Business Overview Table 85. Neos Therapeutics Attention Deficit Hyperactivity Disorder Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Neos Therapeutics Attention Deficit Hyperactivity Disorder Therapeutics Product Portfolio Table 87. Neos Therapeutics Recent Development Table 88. Mallinckrodt Company Information Table 89. Mallinckrodt Business Overview Table 90. Mallinckrodt Attention Deficit Hyperactivity Disorder Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Mallinckrodt Attention Deficit Hyperactivity Disorder Therapeutics Product Portfolio Table 92. Mallinckrodt Recent Development Table 93. Amneal Pharmaceuticals Company Information Table 94. Amneal Pharmaceuticals Business Overview Table 95. Amneal Pharmaceuticals Attention Deficit Hyperactivity Disorder Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. Amneal Pharmaceuticals Attention Deficit Hyperactivity Disorder Therapeutics Product Portfolio Table 97. Amneal Pharmaceuticals Recent Development Table 98. North America Attention Deficit Hyperactivity Disorder Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 99. North America Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 100. North America Attention Deficit Hyperactivity Disorder Therapeutics Market Share by Country (2021-2026) Table 101. North America Attention Deficit Hyperactivity Disorder Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 102. North America Attention Deficit Hyperactivity Disorder Therapeutics Market Share Forecast by Country (2027-2032) Table 103. Europe Attention Deficit Hyperactivity Disorder Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 104. Europe Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 105. Europe Attention Deficit Hyperactivity Disorder Therapeutics Market Share by Country (2021-2026) Table 106. Europe Attention Deficit Hyperactivity Disorder Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 107. Europe Attention Deficit Hyperactivity Disorder Therapeutics Market Share Forecast by Country (2027-2032) Table 108. Asia-Pacific Attention Deficit Hyperactivity Disorder Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 109. Asia-Pacific Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 110. Asia-Pacific Attention Deficit Hyperactivity Disorder Therapeutics Market Share by Country (2021-2026) Table 111. Asia-Pacific Attention Deficit Hyperactivity Disorder Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 112. Asia-Pacific Attention Deficit Hyperactivity Disorder Therapeutics Market Share Forecast by Country (2027-2032) Table 113. Latin America Attention Deficit Hyperactivity Disorder Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 114. Latin America Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 115. Latin America Attention Deficit Hyperactivity Disorder Therapeutics Market Share by Country (2021-2026) Table 116. Latin America Attention Deficit Hyperactivity Disorder Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 117. Latin America Attention Deficit Hyperactivity Disorder Therapeutics Market Share Forecast by Country (2027-2032) Table 118. Middle East & Africa Attention Deficit Hyperactivity Disorder Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 119. Middle East & Africa Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 120. Middle East & Africa Attention Deficit Hyperactivity Disorder Therapeutics Market Share by Country (2021-2026) Table 121. Middle East & Africa Attention Deficit Hyperactivity Disorder Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 122. Middle East & Africa Attention Deficit Hyperactivity Disorder Therapeutics Market Share Forecast by Country (2027-2032) Table 123. Research Programs/Design for This Report Table 124. Authors List of This Report Table 125. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Attention Deficit Hyperactivity Disorder Therapeutics Product Image Figure 3. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size (2021-2032) & (US$ Million) Figure 5. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Share by Region: 2025 VS 2032 Figure 6. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Share by Region (2021-2032) Figure 7. North America Attention Deficit Hyperactivity Disorder Therapeutics Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Attention Deficit Hyperactivity Disorder Therapeutics Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Attention Deficit Hyperactivity Disorder Therapeutics Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Attention Deficit Hyperactivity Disorder Therapeutics Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Attention Deficit Hyperactivity Disorder Therapeutics Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Stimulant Image Figure 13. Global Stimulant Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Non-stimulant Image Figure 15. Global Non-stimulant Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size Overview by Type (2021-2032) & (US$ Million) Figure 17. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Share by Type 2025 VS 2032 Figure 18. North America Attention Deficit Hyperactivity Disorder Therapeutics Market Size Share by Type (2021-2032) Figure 19. Europe Attention Deficit Hyperactivity Disorder Therapeutics Market Size Share by Type (2021-2032) Figure 20. Asia-Pacific Attention Deficit Hyperactivity Disorder Therapeutics Market Size Share by Type (2021-2032) Figure 21. Latin America Attention Deficit Hyperactivity Disorder Therapeutics Market Size Share by Type (2021-2032) Figure 22. Middle East and Africa Attention Deficit Hyperactivity Disorder Therapeutics Market Size Share by Type (2021-2032) Figure 23. Hospital Pharmacy Image Figure 24. Global Hospital Pharmacy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 25. Retail Pharmacy Image Figure 26. Global Retail Pharmacy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size Overview by Application (2021-2032) & (US$ Million) Figure 28. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Share by Application 2025 VS 2032 Figure 29. North America Attention Deficit Hyperactivity Disorder Therapeutics Market Size Share by Application (2021-2032) Figure 30. Europe Attention Deficit Hyperactivity Disorder Therapeutics Market Size Share by Application (2021-2032) Figure 31. Asia-Pacific Attention Deficit Hyperactivity Disorder Therapeutics Market Size Share by Application (2021-2032) Figure 32. Latin America Attention Deficit Hyperactivity Disorder Therapeutics Market Size Share by Application (2021-2032) Figure 33. Middle East and Africa Attention Deficit Hyperactivity Disorder Therapeutics Market Size Share by Application (2021-2032) Figure 34. Global Top 5 and 10 Attention Deficit Hyperactivity Disorder Therapeutics Players Market Share by Revenue in 2025 Figure 35. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 36. North America Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 37. North America Attention Deficit Hyperactivity Disorder Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 38. North America Attention Deficit Hyperactivity Disorder Therapeutics Market Share by Country (2021-2032) Figure 39. Europe Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 40. Europe Attention Deficit Hyperactivity Disorder Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 41. Europe Attention Deficit Hyperactivity Disorder Therapeutics Market Share by Country (2021-2032) Figure 42. Asia-Pacific Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 43. Asia-Pacific Attention Deficit Hyperactivity Disorder Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 44. Asia-Pacific Attention Deficit Hyperactivity Disorder Therapeutics Market Share by Country (2021-2032) Figure 45. Latin America Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. Latin America Attention Deficit Hyperactivity Disorder Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Latin America Attention Deficit Hyperactivity Disorder Therapeutics Market Share by Country (2021-2032) Figure 48. Middle East & Africa Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 49. Middle East & Africa Attention Deficit Hyperactivity Disorder Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 50. Middle East & Africa Attention Deficit Hyperactivity Disorder Therapeutics Market Share by Country (2021-2032) Figure 51. Years Considered Figure 52. Research Process Figure 53. Key Executives Interviewed

Scope & coverage.

Types
  • Stimulant
  • Non-stimulant
Applications
  • Hospital Pharmacy
  • Retail Pharmacy
Companies covered
  • Takeda
  • Johnson & Johnson
  • Novartis
  • Eli Lilly
  • Tris Pharma
  • Purdue Parma
  • Noven Pharmaceuticals
  • Neos Therapeutics
  • Mallinckrodt
  • Amneal Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Region (2021-2032)
  5. 1.4.1 Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Region (2021-2026)
  6. 1.4.2 Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Region (2027-2032)
  7. 1.5 Key Regions Attention Deficit Hyperactivity Disorder Therapeutics Market Size (2021-2032)
  8. 1.5.1 North America Attention Deficit Hyperactivity Disorder Therapeutics Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Attention Deficit Hyperactivity Disorder Therapeutics Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Attention Deficit Hyperactivity Disorder Therapeutics Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Attention Deficit Hyperactivity Disorder Therapeutics Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Attention Deficit Hyperactivity Disorder Therapeutics Market Size Growth Rate (2021-2032)
2 Attention Deficit Hyperactivity Disorder Therapeutics Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Stimulant
  3. 2.1.2 Non-stimulant
  4. 2.2 Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Type
  5. 2.2.1 Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size Overview by Type (2021-2032)
  6. 2.2.2 Global Attention Deficit Hyperactivity Disorder Therapeutics Historic Market Size Review by Type (2021-2026)
  7. 2.2.3 Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size Forecasted by Type (2027-2032)
  8. 2.3 Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Regions
  9. 2.3.1 North America Attention Deficit Hyperactivity Disorder Therapeutics Market Size Breakdown by Type (2021-2026)
  10. 2.3.2 Europe Attention Deficit Hyperactivity Disorder Therapeutics Market Size Breakdown by Type (2021-2026)
  11. 2.3.3 Asia-Pacific Attention Deficit Hyperactivity Disorder Therapeutics Market Size Breakdown by Type (2021-2026)
  12. 2.3.4 South America Attention Deficit Hyperactivity Disorder Therapeutics Market Size Breakdown by Type (2021-2026)
  13. 2.3.5 Middle East and Africa Attention Deficit Hyperactivity Disorder Therapeutics Market Size Breakdown by Type (2021-2026)
3 Attention Deficit Hyperactivity Disorder Therapeutics Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Hospital Pharmacy
  3. 3.1.2 Retail Pharmacy
  4. 3.2 Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Application
  5. 3.2.1 Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size Overview by Application (2021-2032)
  6. 3.2.2 Global Attention Deficit Hyperactivity Disorder Therapeutics Historic Market Size Review by Application (2021-2026)
  7. 3.2.3 Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size Forecasted by Application (2027-2032)
  8. 3.3 Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Regions
  9. 3.3.1 North America Attention Deficit Hyperactivity Disorder Therapeutics Market Size Breakdown by Application (2021-2026)
  10. 3.3.2 Europe Attention Deficit Hyperactivity Disorder Therapeutics Market Size Breakdown by Application (2021-2026)
  11. 3.3.3 Asia-Pacific Attention Deficit Hyperactivity Disorder Therapeutics Market Size Breakdown by Application (2021-2026)
  12. 3.3.4 South America Attention Deficit Hyperactivity Disorder Therapeutics Market Size Breakdown by Application (2021-2026)
  13. 3.3.5 Middle East and Africa Attention Deficit Hyperactivity Disorder Therapeutics Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Attention Deficit Hyperactivity Disorder Therapeutics Industry Trends
  2. 4.2 Attention Deficit Hyperactivity Disorder Therapeutics Industry Drivers
  3. 4.3 Attention Deficit Hyperactivity Disorder Therapeutics Industry Opportunities and Challenges
  4. 4.4 Attention Deficit Hyperactivity Disorder Therapeutics Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Attention Deficit Hyperactivity Disorder Therapeutics Revenue (2021-2026)
  2. 5.2 Global Attention Deficit Hyperactivity Disorder Therapeutics Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Attention Deficit Hyperactivity Disorder Therapeutics Key Company Headquarters & Area Served
  4. 5.4 Global Attention Deficit Hyperactivity Disorder Therapeutics Company, Product Type & Application
  5. 5.5 Global Attention Deficit Hyperactivity Disorder Therapeutics Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Attention Deficit Hyperactivity Disorder Therapeutics Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Attention Deficit Hyperactivity Disorder Therapeutics Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Attention Deficit Hyperactivity Disorder Therapeutics Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Takeda
  2. 6.1.1 Takeda Company Information
  3. 6.1.2 Takeda Business Overview
  4. 6.1.3 Takeda Attention Deficit Hyperactivity Disorder Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Takeda Attention Deficit Hyperactivity Disorder Therapeutics Product Portfolio
  6. 6.1.5 Takeda Recent Developments
  7. 6.2 Johnson & Johnson
  8. 6.2.1 Johnson & Johnson Company Information
  9. 6.2.2 Johnson & Johnson Business Overview
  10. 6.2.3 Johnson & Johnson Attention Deficit Hyperactivity Disorder Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Johnson & Johnson Attention Deficit Hyperactivity Disorder Therapeutics Product Portfolio
  12. 6.2.5 Johnson & Johnson Recent Developments
  13. 6.3 Novartis
  14. 6.3.1 Novartis Company Information
  15. 6.3.2 Novartis Business Overview
  16. 6.3.3 Novartis Attention Deficit Hyperactivity Disorder Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Novartis Attention Deficit Hyperactivity Disorder Therapeutics Product Portfolio
  18. 6.3.5 Novartis Recent Developments
  19. 6.4 Eli Lilly
  20. 6.4.1 Eli Lilly Company Information
  21. 6.4.2 Eli Lilly Business Overview
  22. 6.4.3 Eli Lilly Attention Deficit Hyperactivity Disorder Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Eli Lilly Attention Deficit Hyperactivity Disorder Therapeutics Product Portfolio
  24. 6.4.5 Eli Lilly Recent Developments
  25. 6.5 Tris Pharma
  26. 6.5.1 Tris Pharma Company Information
  27. 6.5.2 Tris Pharma Business Overview
  28. 6.5.3 Tris Pharma Attention Deficit Hyperactivity Disorder Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Tris Pharma Attention Deficit Hyperactivity Disorder Therapeutics Product Portfolio
  30. 6.5.5 Tris Pharma Recent Developments
  31. 6.6 Purdue Parma
  32. 6.6.1 Purdue Parma Company Information
  33. 6.6.2 Purdue Parma Business Overview
  34. 6.6.3 Purdue Parma Attention Deficit Hyperactivity Disorder Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Purdue Parma Attention Deficit Hyperactivity Disorder Therapeutics Product Portfolio
  36. 6.6.5 Purdue Parma Recent Developments
  37. 6.7 Noven Pharmaceuticals
  38. 6.7.1 Noven Pharmaceuticals Company Information
  39. 6.7.2 Noven Pharmaceuticals Business Overview
  40. 6.7.3 Noven Pharmaceuticals Attention Deficit Hyperactivity Disorder Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Noven Pharmaceuticals Attention Deficit Hyperactivity Disorder Therapeutics Product Portfolio
  42. 6.7.5 Noven Pharmaceuticals Recent Developments
  43. 6.8 Neos Therapeutics
  44. 6.8.1 Neos Therapeutics Company Information
  45. 6.8.2 Neos Therapeutics Business Overview
  46. 6.8.3 Neos Therapeutics Attention Deficit Hyperactivity Disorder Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Neos Therapeutics Attention Deficit Hyperactivity Disorder Therapeutics Product Portfolio
  48. 6.8.5 Neos Therapeutics Recent Developments
  49. 6.9 Mallinckrodt
  50. 6.9.1 Mallinckrodt Company Information
  51. 6.9.2 Mallinckrodt Business Overview
  52. 6.9.3 Mallinckrodt Attention Deficit Hyperactivity Disorder Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Mallinckrodt Attention Deficit Hyperactivity Disorder Therapeutics Product Portfolio
  54. 6.9.5 Mallinckrodt Recent Developments
  55. 6.10 Amneal Pharmaceuticals
  56. 6.10.1 Amneal Pharmaceuticals Company Information
  57. 6.10.2 Amneal Pharmaceuticals Business Overview
  58. 6.10.3 Amneal Pharmaceuticals Attention Deficit Hyperactivity Disorder Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 Amneal Pharmaceuticals Attention Deficit Hyperactivity Disorder Therapeutics Product Portfolio
  60. 6.10.5 Amneal Pharmaceuticals Recent Developments
7 North America
  1. 7.1 North America Attention Deficit Hyperactivity Disorder Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Country (2021-2026)
  3. 7.3 North America Attention Deficit Hyperactivity Disorder Therapeutics Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Attention Deficit Hyperactivity Disorder Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Country (2021-2026)
  3. 8.3 Europe Attention Deficit Hyperactivity Disorder Therapeutics Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Attention Deficit Hyperactivity Disorder Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Attention Deficit Hyperactivity Disorder Therapeutics Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Attention Deficit Hyperactivity Disorder Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Country (2021-2026)
  3. 10.3 South America Attention Deficit Hyperactivity Disorder Therapeutics Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Attention Deficit Hyperactivity Disorder Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Attention Deficit Hyperactivity Disorder Therapeutics Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst